Vulvovaginal candidiasis

Obstetrics and Gynecology Clinics of North America

Volumn 30, Issue 4, 2003, Pages 671-684

  Nyirjesy, Paul ^a,c   Sobel, Jack D ^b  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c New College Building   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; BORIC ACID; BUTOCONAZOLE; CLOTRIMAZOLE; ESTROGEN; FLUCONAZOLE; FLUCYTOSINE; KETOCONAZOLE; MICONAZOLE; NYSTATIN; ORAL CONTRACEPTIVE AGENT; TAMOXIFEN; TERCONAZOLE; TIOCONAZOLE;

BACTERIUM IDENTIFICATION; BURNING SENSATION; CANDIDA ALBICANS; DIAGNOSTIC ERROR; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG COST; DRUG FORMULATION; EPIDEMIOLOGICAL DATA; GASTROINTESTINAL SYMPTOM; HEADACHE; HEALTH CARE COST; HUMAN; INFECTION RISK; LIVER TOXICITY; PATHOGENESIS; PH MEASUREMENT; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RASH; REVIEW; RISK FACTOR; SELF MEDICATION; SIDE EFFECT; SUSTAINED RELEASE PREPARATION; VAGINA CANDIDIASIS;

EID: 0345731362     PISSN: 08898545     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8545(03)00083-4     Document Type: Review

References (49)

1. Kent HL. Epidemiology of vaginitis. Am J Obstet Gynecol 1991;165:1168-76.
2. Foxman B, Barlow R, D'Arcy H, Gillespie B, Sobel JD. Candida vaginitis: self-reported incidence and associated costs. Sex Transm Dis 2000;27:230-5.
3. Sobel JD, Faro S, Force RW, Foxman B, Ledger WJ, Nyirjesy P, et al. Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol 1998;178:203-11.
4. Sobel JD, Brooker D, Stein GE, Thomason J, Wermeling DP, Weinstein L, et al. Single oral dose fluconazole compared with conventional topical therapy of Candida vaginitis. Am J Obstet Gynecol 1995;172:1263-8.
5. Sobel JD, Kapernick PS, Zervos M, Reed BD, Hooton T, Soper D, et al. Treatment of complicated Candida vaginitis: comparison of single and sequential doses of fluconazole. Am J Obstet Gynecol 2001;185:363-9.
6. Nyirjesy P, Seeney SM, Grody MHT, Jordan CA, Buckley HR. Chronic fungal vaginitis: the value of cultures. Am J Obstet Gynecol 1995;173:820-3.
7. Sobel JD, Hillier S, Smolenski L, Martens M, Danna P, Panzer H, et al. Management of recurrent vulvovaginal candidiasis (RVVC) with maintenance suppressive weekly fluconazole: a multicenter study [abstract LB-8]. In: Programs and abstracts of the 42nd Interscience Conference of Antimicrobial Agents and Chemotherapy. San Diego; September 27-30, 2002.
8. Hurley R, Delouvois J. Candida vaginitis. Postgrad Med J 1979;55:645-7.
9. Geiger AM, Foxman B. Risk factors for vulvovaginal candidiasis: a case-control study among university students. Epidemiology 1996;7:182-7.
10. Foxman B, Marsh JV, Gillespie B, Sobel JD. Frequency and response to vaginal symptoms among white and African American women: results of a random digit dialing survey. J Womens Health 1998;7(9):1167-74.
11. Ohmit SE, Sobel JD, Schuman P, Duerr A, et al. A longitudinal study of mucosal Candida colonization and candidiasis among HIV-seropositive and at-risk HIV-seronegative women. J Infect Dis 2003;188:118-27.
12. Vazquez JA, Sobel JD, Demitriou R, Vaishampayan J, Lynch M, Zervos MJ. Karyotyping of Candida albicans isolates obtained longitudinally in women with recurrent vulvovaginal candidiasis. J Infect Dis 1994;170:1566-9.
13. Lynch ME, Sobel JD. Comparative in vitro activity of antimycotic agents against pathogenic vaginal yeast isolates. J Med Vet Mycol 1994;32:267-74.
14. Sobel J, Zervos M, Reed BD, Hooton T, Soper D, Nyirjesy P, et al. Fluconazole susceptibility of vaginal isolates obtained from women with complicated Candida vaginitis: clinical implications. Antimicrob Agents Chemother 2003;47(1):34-8.
15. DeLeon EM, Jacober SJ, Sobel JD, Foxman B. Prevalence and risk factors for vaginal Candida colonization in women with type I and type II diabetes. BMC Infect Dis 2002;2:1-11.
16. Donders GG, Prenen H, Verbeke G, Reybrouck R. Impaired tolerance for glucose in women with recurrent vaginal candidiasis. Am J Obstet Gynecol 2002;187:989-93.
17. Spinillo A, Capuzzo E, Acciano S, DeSantolo A, Zara F. Effect of antibiotic use on the prevalence of symptomatic vulvovaginal candidiasis. Am J Obstet Gynecol 1999;180:14-7.
18. Hawes SE, Hillier SL, Benedetti J, Stevens CE, Koutsky LA, Wolner-Hannsen P, et al. Hydrogen peroxide-producing lactobacilli and acquisition of vaginal infections. J Infect Dis 1996;174:1058-63.
19. Reed BD, Gorenflo DW, Gillespie BW, Pierson CL, Zazove P. Sexual behaviors and other risk factors for Candida vulvovaginitis. J Womens Health Gend Based Med 2000;9:645-55.
20. Sobel JD, Chaim W, Leaman D. Recurrent vulvovaginal candidiasis associated with long-term tamoxifen treatment in postmenopausal women. Obstet Gynecol 1996;88:704-6.
21. Hooten TM, Roberts PL, Stamm WE. Effect of recent sexual activity and use of diaphragm on vaginal flora. Clin Infect Dis 1994;19:274-8.
22. Barbone F, Austin H, Louv WC, Alexander WJ. A follow-up study of methods of contraception, sexual activity, and rates of trichomoniasis, candidiasis, and bacterial vaginosis. Am J Obstet Gynecol 1990;163:510-4.
23. Spinillo A, Capuzzo E, Egbe TO, Baltaro F, Nicola S, Piazzi G. Torulopsis glabrata vaginitis. Obstet Gynecol 1995;85:993-8.
24. Giraldo P, von Nowaskonski A, Gomes FA, Linhares I, Neves NA, Witkin SS. Vaginal colonization by Candida in asymptomatic women with and without a history of recurrent vulvovaginal candidiasis. Obstet Gynecol 2000;95:413-6.
25. Chaim W, Foxman B, Sobel JD. Association of recurrent vaginal candidiasis and secretory ABO and Lewis phenotype. J Infect Dis 1997;176:828-30.
26. Nyirjesy P, Weitz MV, Grody MHT, Lorber B. Over-the-counter and alternative medicines in the treatment of chronic vaginal symptoms. Obstet Gynecol 1997;90:50-3.
27. Hilton E, Isenberg HD, Alperstein P, France K, Borenstein MT. Ingestion of yogurt containing Lactobacillus acidophilus as prophylaxis for candidal vaginitis. Ann Intern Med 1992;116:353-7.
28. Sobel JD, Chaim W. Vaginal microbiology of women with acute recurrent vulvovaginal candidiasis. J Clin Microbiol 1996;34:2497-9.
29. Fidel Jr PL, Sobel JD. Immunopathogenesis of recurrent vulvovaginal candidiasis. Clin Microbiol Rev 1996;9:335-48.
30. Barousse MM, Steele C, Dunlap K, Espinosa T, Boikov D, Sobel JD, et al. Growth inhibition of Candida albicans by human vaginal epithelial cells. J Infect Dis 2001;184:1489-93.
31. Bergman JJ, Berg AO, Schneeweiis R, Heidrich FE. Clinical comparison of microscopic and culture techniques in the diagnosis of Candida vaginitis. J Fam Pract 1984;18:549-52.
32. Ledger WJ, Polaneczky MM, Yih MC, Jeremias J, Tolbert V, Witkin SS. Difficulties in the diagnosis of Candida vaginitis. Infect Dis Clin Pract 2000;9:66-9.
33. Chaponis RJ, Bresnick PA, Weiss RR, Edwards LD. Candida vaginitis: signs and symptoms aid women's self-recognition. J Clin Res Drug Dev 1993;7:17-23.
34. Lipsky MS, Waters T, Sharp LK. Impact of vaginal antifungal products on utilization of health care services: evidence from physician visits. J Am Board Fam Pract 2000;13:178-82.
35. Ferris DG, Dekle C, Litaker MS. Women's use of over-the-counter antifungal medications for gynecological symptoms. J Fam Pract 1996;42:595-600.
36. Ferris DG, Nyirjesy P, Sobel JD, Soper D, Pavletic A, Litaker MS. Over-the-counter antifungal drug misuse associated with patient-diagnosed vulvovaginal candidiasis. Obstet Gynecol 2002;99:419-25.
37. Allen-Davis JT, Beck A, Parker R, Ellis J, Polley D. Assessment of vulvovaginal complaints: accuracy of telephone triage and in-office diagnosis. Obstet Gynecol 2002;99:18-22.
38. Wiesenfeld HC, Macio I. The infrequent use of office-based diagnostic tests for vaginitis. Am J Obstet Gynecol 1999;181:39-41.
39. Slavin MB, Benrubi GI, Parker R, Griffin CR, Magee MJ. Single dose oral fluconazole vs intravaginal terconazole in treatment of Candida vaginitis: comparison and pilot study. J Fla Med Assoc 1992;79:693-6.
40. Mastroiacovo P, Mazzone T, Botto LD, Serafini MA, Finardi A, Caramelli L, et al. Prospective assessment of pregnancy outcomes after first-trimester exposure to fluconazole. Am J Obstet Gynecol 1996;175:1645-50.
41. Tooley PJ. Patients and doctor preferences in the treatment of vaginal candidiasis. Practitioner 1990;71:73-6.
42. Sobel JD. Recurrent vulvovaginal candidiasis: a prospective study of the efficacy of maintenance ketoconazole therapy. N Engl J Med 1986;315:1455-8.
43. Davidon F, Mould RF. Recurrent genital candidosis in women and the effect of intermittent prophylactic treatment. Br J Vener Dis 1978;54:176-83.
44. Fong IW. The value of treating the sexual partners of women with recurrent vaginal candidiasis with ketoconazole. Genitourin Med 1992;68:174-6.
45. Sood G, Nyirjesy P, Weitz MV, Chatwani A. Terconazole cream for non-Candida albicans fungal vaginitis: results of a retrospective analysis. Infect Dis Obstet Gynecol 2000;8:240-3.
46. Singh S, Sobel JD, Bhargava P, Boikov D, Vazquez JA. Vaginitis due to Candida krusei: epidemiology, clinical aspects, and therapy. Clin Infect Dis 2002;35:1066-70.
47. Sobel JD, Chaim W. Treatment of Candida glabrata vaginitis: a retrospective review of boric acid therapy. Clin Infect Dis 1997;24:649-52.
48. Horowiz B. Topical flucytosine for chronic recurrent Candida tropicalis infections. J Reprod Med 1986;31:821-4.
49. Sobel JD, Chaim W, Nagappan V, Leaman D. Treatment of vaginitis due to C. glabrata: use of topical boric acid and flucytosine. Am J Obstet Gynecol, in press.